BiotechTube

clopidogrel (SR25990C)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cerebral Infarction

Conditions

Cerebral Infarction

Trial Timeline

Sep 1, 2006 → Dec 1, 2008

NCT ID
NCT00386191

About clopidogrel (SR25990C)

clopidogrel (SR25990C) is a approved stage product being developed by Sanofi for Cerebral Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00386191. Target conditions include Cerebral Infarction.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT00386191ApprovedCompleted
NCT00325390Phase 3Completed

Competing Products

20 competing products in Cerebral Infarction

See all competitors
ProductCompanyStageHype Score
mouse nerve growth factorSun PharmaceuticalApproved
85
Edaravone Dexborneol + PlaceboSun PharmaceuticalPhase 2
52
Oral Glycopyrrolate LiquidShionogiPhase 3
77
recombinant human erythropoietin alfa + 0.9% NaClJohnson & JohnsonPhase 2/3
65
UDI-001Rohto PharmaceuticalPhase 1/2
41
NXY-059AstraZenecaPhase 3
77
NXY-059AstraZenecaPhase 2
52
RosuvastatinAstraZenecaApproved
85
NXY-059AstraZenecaPhase 3
77
Comparator: Placebo + Comparator: MK0724MerckPhase 2
52
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mgMerckPhase 2
52
Recombinant Factor VIIa + Biological/Vaccine: PlaceboNovo NordiskPhase 3
76
Recombinant Activated Factor VII (rFVIIa) + PlaceboNovo NordiskPhase 3
76
PonezumabPfizerPhase 2
51
PF-05230907PfizerPhase 1
32
Azithromycin + Pyrimethamine + Leucovorin calciumPfizerPhase 1
32
Intrarectal quinineSanofiPhase 3
76
PiracetamUCBApproved
82
Placebo + ALN-APPAlnylam PharmaceuticalsPhase 2
49
CN-105Tiantan BioPhase 2
49

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84